Corvus Pharmaceuticals CRVS Accrued Liabilities, Current
Accrued Liabilities, Current at other companies
Other financials
Where this comes from
Reported directly by Corvus Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:AccruedLiabilitiesCurrent.
The official record: Corvus Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Corvus Pharmaceuticals's accrued liabilities, current.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Corvus Pharmaceuticals's accrued liabilities, current?
- Corvus Pharmaceuticals (CRVS) reported accrued liabilities, current of $6.99M in Q1 2026.
- How has Corvus Pharmaceuticals's accrued liabilities, current changed year-over-year?
- Corvus Pharmaceuticals's accrued liabilities, current increased by 80.4% year-over-year, from $3.87M to $6.99M.
- What is the long-term trend for Corvus Pharmaceuticals's accrued liabilities, current?
- Over 2 years (2023 to 2025), Corvus Pharmaceuticals's accrued liabilities, current has grown at a 27.8% compound annual growth rate (CAGR), from $3.97M to $6.49M.